- Home
- SQFTW vs GNLX Comparison
SQFTW vs GNLX Comparison
Compare SQFTW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFTW
- GNLX
- Stock Information
- Founded
- SQFTW N/A
- GNLX 2001
- Country
- SQFTW United States
- GNLX United States
- Employees
- SQFTW 15
- GNLX N/A
- Industry
- SQFTW Real Estate Investment Trusts
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SQFTW Real Estate
- GNLX Health Care
- Exchange
- SQFTW Nasdaq
- GNLX Nasdaq
- Market Cap
- SQFTW N/A
- GNLX 103.6M
- IPO Year
- SQFTW N/A
- GNLX 2023
- Fundamental
- Price
- SQFTW $0.03
- GNLX $2.27
- Analyst Decision
- SQFTW
- GNLX Strong Buy
- Analyst Count
- SQFTW 0
- GNLX 4
- Target Price
- SQFTW N/A
- GNLX $18.25
- AVG Volume (30 Days)
- SQFTW N/A
- GNLX 141.5K
- Earning Date
- SQFTW N/A
- GNLX 11-14-2024
- Dividend Yield
- SQFTW N/A
- GNLX N/A
- EPS Growth
- SQFTW N/A
- GNLX N/A
- EPS
- SQFTW N/A
- GNLX N/A
- Revenue
- SQFTW N/A
- GNLX $8,000.00
- Revenue This Year
- SQFTW N/A
- GNLX N/A
- Revenue Next Year
- SQFTW N/A
- GNLX N/A
- P/E Ratio
- SQFTW N/A
- GNLX N/A
- Revenue Growth
- SQFTW N/A
- GNLX N/A
- 52 Week Low
- SQFTW N/A
- GNLX $1.60
- 52 Week High
- SQFTW N/A
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- SQFTW N/A
- GNLX 38.68
- Support Level
- SQFTW N/A
- GNLX $2.13
- Resistance Level
- SQFTW N/A
- GNLX $2.80
- Average True Range (ATR)
- SQFTW 0.00
- GNLX 0.20
- MACD
- SQFTW 0.00
- GNLX -0.04
- Stochastic Oscillator
- SQFTW 0.00
- GNLX 14.21
About SQFTW Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.